Document is current
Any future updates will be listed below
-
Authors
Pan, Yi
Yang, Xuening https://orcid.org/0000-0002-8346-2117
Zhou, Qing
Zhao, Yanqiu
Han, Guang
Pang, Qingsong
Zhang, Zhenfa
Wang, Qifeng
Yao, Jun
Wang, Hui
Yang, Weihua
Liu, Baogang
Chen, Qixun
Du, Xianghui
Cai, Kaican
Li, Baosheng
Huang, Yunchao
Li, Xiao
Jia, Yijun
Song, Li
Shi, Wei
Wu, Yi-Long https://orcid.org/0000-0002-3611-0258
-
Funding
Funding for this research was provided by:
Jiangsu Hengrui Pharmaceuticals
- License Information
-
More Information
Article History
Received: 13 October 2025
Revised: 23 March 2026
Accepted: 30 April 2026
First Online: 16 June 2026
Competing interests
: Disclosures for Y.-L.W. include honoraria received from AstraZeneca, Roche, Pfizer, Boehringer Ingelheim, Lilly, MSD Oncology, Bristol-Myers Squibb, and Hengrui. Additionally, Y.-L.W. served in a consulting or advisory capacity for AstraZeneca, Boehringer Ingelheim, Roche, and Takeda while receiving research support from Roche, Boehringer Ingelheim, Pfizer, and Bristol-Myers Squibb. Q.Z. received honoraria from AstraZeneca, Roche, Pfizer, Lilly, Boehringer Ingelheim, Bristol-Myers Squibb, MSD Oncology, and Hengrui. X.L., Y.J., L.S., and W. S. declare employment at Jiangsu Hengrui Pharmaceuticals. All remaining authors have no competing interests to disclose.
